Skip to main content

Table 2 Histopathological assessment of mice treated with DOTA_Miltuximab®, 3Mbq [177Lu]Lu-DOTA-Miltuximab® or 10Mbq [177Lu]Lu-DOTA-Miltuximab®

From: Targeted beta therapy of prostate cancer with 177Lu-labelled Miltuximab® antibody against glypican-1 (GPC-1)

 DOTA-Miltuximab®3Mbq [177Lu]Lu-DOTA-Miltuximab®10Mbq [177Lu]Lu-DOTA-Miltuximab®
Mouse number
Organ4.14.24.45.15.25.35.41.11.43.33.46.16.26.36.41.21.31.52.12.22.32.43.13.2
Brain000000000000000000000000
Heart
 Vasculitis, focal004000000000000000000000
 Epicardial mineralisation000000002020000000000000
Lung
 Inflammation, granulomatous00NT000000000000000000000
 Perivascular lymphocytes00NT000000000000000002010
Liver
 Neutrophilic infiltrate000000000000001000020000
 Mononuclear/mixed cell infiltrate011110030111001111320100
 Fatty change000000000010001000010010
Kidneys
 Tubular epithelial basophilia, cortex110111100001010110001111
 Inflammation, interstitial, cortex100100010011000121012111
 Pyelonephritis000000000000030000000000
Spleen000000000000000000000000
Small intestine000000000000000000000000
Testes000000110010100010000000
  1. NT not tested
  2. 0 = no abnormalities, 1 = minimal, 2 = mild, 3 = moderate, 4 = severe